First Patient Dosed in Phase 1b Trial of Sitravatinib-Tislelizumab Combo for Advanced Solid Tumors
News
A Phase 1b clinical trial studying a combination of Mirati Therapeutics‘ small molecule inhibitor sitravatinib and BeiGene‘s immune checkpoint inhibitor tislelizumab has begun dosing ... Read more